Leaf has assisted Cerba Research to join forces with ACT Genomics under a joint venture model to create a purpose-built lab facility in Taiwan covering the Asia Pacific region.<\/p>\n\n\n\n
Cerba Research is a leading global clinical trial laboratory services organization owned by Cerba HealthCare. This expansion of the precision medicine offering includes central labs, flow cytometry, histopathology, and translational science laboratory services.<\/p>\n\n\n\n
Leaf has assisted Cerba Research in the drafting of the contractual documentation, structuring and negotiation of this cross-border transaction between Europe and Asia.<\/p>\n\n\n\n
This joint venture and this strategic alliance will support new growth areas for biotech and pharma clients globally and drive better patient outcomes across all phases of clinical trials<\/em>, confirms Jean-Philippe Engel<\/a>, Partner at Leaf.<\/p>\n\n\n\n The expansion includes investments in a new facility in Taipei and state-of-the-art technologies to strengthen capabilities and services offered to Cerba clients.<\/p>\n\n\n\n Mario Papillon<\/a>, CEO of Cerba Research comments: \u201cThis milestone with ACT Genomics validates our innovative history as a company. We will support our customers with the latest instrumentation and automation \u2014 backed by experienced scientists whose ambition and agility to meet patients\u2019 needs drive our continuous evolution as a company.\u201d<\/em><\/p>\n\n\n\n \u201cWe are excited to create a partnership with Cerba Research. Together, we offer a broader range of top-notch technologies and services in Asia. The formation of CerbACT Asia echoes our firm dedication in the well-being of cancer patients, keen commitment to society, and unequivocal embrace of precision medicine,\u201d<\/em> says Hua Chien Chen, CEO, ACT Genomics.<\/p>\n\n\n\n \u201cThis strategic partnership represents a milestone in medical research for Asia and we are proud to have assisted in the formation of CerbACT, demonstrating once again the expertise Leaf has in cross-border transactions in the medical sector.\u201d<\/em> said Bruno Grangier<\/a>, Partner at Leaf.<\/p>\n\n\n\n Cerba Research is a leading healthcare company with end-to-end drug development and diagnostic solutions to optimize R&D drug productivity and commercialization. Providing Early phase research, clinical development through central laboratory and diagnostic services, Assay and biomarker development and validation. Working with government agencies, non-government organisations as well as pharma and biotech organisations to change the shape of clinical development. Cerba Research is part of Cerba HealthCare, a leading player in medical diagnosis. For more information: www.cerbaresearch.com<\/a><\/p>\n\n\n\n ACT Genomics is an innovation-driven cancer solution provider in Asia with offices in Taipei, Hong Kong, Singapore & Tokyo. With our Next-Generation Sequencing (NGS) technology, CAP-accredited laboratories, experienced bioinformatics team and proprietary AI algorithms, we provide optimal cancer treatment planning, immunotherapy evaluation, cancer relapse & drug resistance monitoring, as well as cancer risk assessment services to medical professionals. Together, we \u201cTurn Genomics into Action.\u201d <\/p>\n\n\n\nAbout Cerba Research<\/h2>\n\n\n\n
<\/p>\n\n\n\nAbout ACT Genomics <\/h2>\n\n\n\n